Brexpiprazole is used for treating major depressive disorder (MDD) and schizophrenia in adults and pediatric patients ages 13 years and older. It was first introduced by Otsuka Pharmaceutical Co Ltd in its drug Rexulti on Jul 10, 2015. 11 different companies have introduced drugs containing Brexpiprazole.

Brexpiprazole Patents

Given below is the list of patents protecting Brexpiprazole, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Rexulti	US10307419	Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof	Oct 12, 2032	Otsuka
Rexulti	US10307419 (Pediatric)	Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof	Apr 12, 2033	Otsuka
Rexulti	US7888362	Piperazine-substituted benzothiophenes for treatment of mental disorders	Apr 12, 2026	Otsuka
Rexulti	US7888362 (Pediatric)	Piperazine-substituted benzothiophenes for treatment of mental disorders	Oct 12, 2026	Otsuka
Rexulti	US8349840	Piperazine-substituted benzothiophenes for treatment of mental disorders	Apr 12, 2026	Otsuka
Rexulti	US8349840 (Pediatric)	Piperazine-substituted benzothiophenes for treatment of mental disorders	Oct 12, 2026	Otsuka
Rexulti	US8618109	Piperazine-substituted benzothiophenes for treatment of mental disorders	Apr 12, 2026	Otsuka
Rexulti	US8618109 (Pediatric)	Piperazine-substituted benzothiophenes for treatment of mental disorders	Oct 12, 2026	Otsuka
Rexulti	US9839637	Piperazine-substituted benzothiophenes for treatment of mental disorders	Apr 12, 2026	Otsuka
Rexulti	US9839637 (Pediatric)	Piperazine-substituted benzothiophenes for treatment of mental disorders	Oct 12, 2026	Otsuka
Rexulti	USRE48059	Piperazine-substituted benzothiophenes for treatment of mental disorders	Dec 23, 2028	Otsuka
Rexulti	USRE48059 (Pediatric)	Piperazine-substituted benzothiophenes for treatment of mental disorders	Jun 23, 2029	Otsuka

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Brexpiprazole's patents.

Latest Legal Activities on Brexpiprazole's Patents

Given below is the list recent legal activities going on the following patents of Brexpiprazole.

Event	Date	Patent/Publication
Legal Activities for all Patents
Payment of Maintenance Fee, 12th Year, Large Entity	26 Jun, 2024	US8349840
Payment of Maintenance Fee, 4th Year, Large Entity	16 Nov, 2022	US10307419
Payment of Maintenance Fee, 8th Year, Large Entity	16 Jun, 2021	US8618109
Payment of Maintenance Fee, 4th Year, Large Entity	26 May, 2021	US9839637
Mail-Petition Decision - Granted	08 Oct, 2020	US7888362
Petition Decision - Granted	06 Oct, 2020	US7888362
Petition Entered	06 Jul, 2020	US7888362
Payment of Maintenance Fee, 8th Year, Large Entity	25 Jun, 2020	US8349840
Mail Certificate of Correction Memo	27 Sep, 2019	US10307419
Post Issue Communication - Certificate of Correction	26 Sep, 2019	US10307419

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳